AZEDRA® (iobenguane I 131) in patients with malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL): final results of a multi-center, open-label, pivotal phase 2b study
AZEDRA® (iobenguane I 131) in patients with malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL): final results of a multi-center, open-label, pivotal phase 2b study
share this article / event
Catagories / Archives
let’s stay in touch!
Stay up to date with the latest research and news, events we are hosting, and other organizations that we are participating with as we move forward to find a cure!
